Clinical Trials News
Newly Open Protocols
ECOG E-1105 - A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer.
RTOG 0126 - A phase III randomized study of high dose 3D-CRT/IMRT versus standard dose 3D-CRT/IMRT in patients treated for localized prostate cancer.
RTOG 0615 - A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer.
RTOG 0617 - A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy With Concurrent And Consolidation Carboplatin/Paclitaxel In Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer.
SWOG S0600 - Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX.
IDPH - Incorporating Reproductive Health in Breast Cancer Care.
For more information on open protocols follow this link.
Pending Protocols
RTOG 0417 - A Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma.
Temporarily Suspended Protocols
ECOG E-4A03 - A Randomized Phase III Study of CC-5013 Plus Dexamethasone vs. CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders.
Recently Closed Protocols
IBCSG 24-02 SOFT - A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT).
IBCSG 25-02 TEXT - A Phase III Trial Evaluating the Role of Exemestane + GnRH Analogue as Adjuvant Therapy for Premenopausal Women w/ Endocrine Responsive Breast Cancer (TEXT).
NSABP B-37 - A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer.
